Short answer: Dapagliflozin has a half-life of about 12.9 hours. Levels peak within 2 hours after a dose. People vary, so treat these as estimates.
Dapagliflozin is an SGLT2 inhibitor: it makes the kidneys pass more sugar into the urine. It is sold as Farxiga, a once-daily tablet approved for chronic kidney disease, heart failure and type 2 diabetes.
Also known as: Farxiga.
Farxiga comes as 5 mg and 10 mg tablets.
The FDA Farxiga label approves it to slow kidney decline in adults with chronic kidney disease; to lower the risk of heart-related death and heart failure hospital stays in adults with heart failure; to lower heart failure hospital stays in adults with type 2 diabetes and heart disease or risk factors; and, with diet and exercise, to improve blood sugar in adults and children 10 and older with type 2 diabetes. For blood sugar the label starts at 5 mg once a day and may go to 10 mg; for the other uses it is 10 mg once a day. It is not for blood sugar control in type 1 diabetes, or for blood sugar when eGFR is below 45.
Like other SGLT2 inhibitors, its first listed serious risk is ketoacidosis, which can happen with near-normal blood sugar; the label says to stop it at least 3 days before surgery or long fasting if possible. It can also cause dehydration, genital yeast infections and urinary infections. See the Farxiga side effects and missed dose pages.
The FDA Farxiga label gives a mean terminal half-life of about 12.9 hours after a single 10 mg dose and peak levels usually within 2 hours when fasting. Bioavailability of a 10 mg dose is 78%. A high-fat meal lowers the peak by up to 50% and delays it by about 1 hour, but the label says it can be taken with or without food.
Numbers shown are taken from the source above. Half-life varies from person to person.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator